CG Equity Research

CG Equity Research
electroCore, Inc.
(NASDAQ: ECOR)
Request  Meeting
OUTPERFORM
CG Rating
$20.00
Price Target
+108%
Upside
Key Investment Highlights
1
Accelerating Revenue Growth
20%+ year-over-year growth driven by VA, prescription, and fast-scaling consumer channels.
2
High-Margins, Scalable Model
An 85–87% gross margin business positioned to scale toward EBITDA breakeven as revenue expands.
3
Expanding Bioelectronic Platform
FDA-cleared migraine and fibromyalgia therapies with growing wellness and military applications.
Latest Research Reports
11.06.25: ECOR: Bioelectric Company Posts Record Revenue, Raised Guidance, and Strength in Both VA and Wellness Channelso
12.23.24: ECOR: A Holiday Gift for Shareholders: electroCore Expands Its Bioelectronic Portfolio with Game-Changing Quell Acquisition
5.6.24: ECOR: 1Q Preview: Remaining Aggressive, Reiterate OUTPERFORM, Price Target of $30
ECOR: 12-Month Performance
Contact Us
For detailed financial projections, clinical data, regulatory pathway, and commercialization strategy, contact ecor@cg.capital to access additional investor materials.
Learn More
Contact Us